EPCAM and ovarian cancer: In a study by the OVCAD Consortium [30], the authors used a sophisticated approach to detect EpCAM+ ovarian cancer CTCs, which included parallel assessment with qPCR and immunofluorescent staining in blood samples obtained before and after primary treatment (6 months after the adjuvant CT completion).